Sorrento's COVID-19 Main Protease Inhibitor Neutralizes Omicron

Sorrento Therapeutics Inc's (NASDAQ: SRNE) late-stage preclinical Mpro inhibitor, STI-1558, effectively inhibits omicron virus entry and replication in cell-based assays.

• In VeroE6 cells challenged with omicron variant, STI-1558 alone (without efflux inhibitor) showed significant antiviral activity with an EC50 value of 360 nM, equivalent to that seen against the Delta variant (EC50 value, 370 nM).

• Related: Sorrento Therapeutics' COVID-19 Antibody Works Against Omicron Variant.

• In an omicron S protein-mediated pseudovirus entry assay, STI-1558 effectively inhibited pseudovirus entry into cells, whereas EUA-approved Pfizer Inc's (NYSE: PFE) nirmatrelvir (Paxlovid) showed no inhibition.

• STI-1558 showed improved human liver metabolic stability compared to nirmatrelvir, and its oral bioavailability does not depend on the ritonavir co-administration.

• Without the need to co-administer Ritonavir, STI-1558 potentially avoids significant adverse drug-drug interactions.

• Price Action: SRNE shares are down 0.35% at $2.87 during the market session on the last check Friday.

See more from Benzinga

• Sorrento Therapeutics' COVID-19 Antibody Works Against Omicron Variant

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.